Table 3 Univariate and multivariate analysis of factors associated with 14-day mortality
Characteristic | Total | Survivors | Non-survivors | P value | Multivariate analysis | |
|---|---|---|---|---|---|---|
(n = 285) | (n = 231) | (n = 54) | HR (95% CI) | P value | ||
Demographic data | ||||||
Age (years), mean (±SD) | 56.8 ± 15.9 | 56.7 ± 16.4 | 57.2 ± 14.1 | 0.83 | ||
Male sex | 199 (69.8) | 159 (68.8) | 40 (74.1) | 0.45 | ||
ICU hospitalization | 69 (24.2) | 48 (20.8) | 21 (38.9) | 0.005 | ||
Nosocomial acquisition | 206 (72.3) | 158 (68.4) | 48 (88.9) | 0.002 | ||
Underlying diseases | ||||||
Diabetes | 63 (22.1) | 52 (22.5) | 11 (20.4) | 0.73 | ||
Hematologic malignancy | 31 (10.9) | 23 (10.0) | 8 (14.8) | 0.30 | ||
Solid tumor | 67 (23.5) | 60 (26.0) | 7 (13.0) | 0.04 | ||
Solid organ transplantation | 33 (11.6) | 24 (10.4) | 9 (16.7) | 0.19 | ||
Heart disease | 35 (12.3) | 23 (10.0) | 12 (22.2) | 0.01 | ||
Chronic lung disease | 28 (9.8) | 25 (10.8) | 3 (5.6) | 0.24 | ||
Chronic kidney disease | 62 (21.8) | 38 (16.5) | 24 (44.4) | < 0.001 | ||
Origin of BSI | ||||||
Respiratory tract | 49 (17.2) | 28 (12.1) | 21 (38.9) | < 0.001 | ||
Intraabdominal | 36 (12.6) | 26 (11.3) | 10 (18.5) | 0.15 | ||
Soft tissue | 10 (3.5) | 6 (2.6) | 4 (7.4) | 0.19 | ||
Intravenous catheter | 10 (3.5) | 9 (3.9) | 1 (1.9) | 0.75 | ||
Urinary tract | 14 (4.9) | 14 (6.1) | 0 | 0.13 | ||
Biliary tract | 52 (18.2) | 51 (22.1) | 1 (1.9) | 0.001 | ||
Liver abscess | 28 (9.8) | 28 (12.1) | 0 | 0.007 | ||
Unknown | 72 (25.3) | 60 (26.0) | 12 (22.2) | 0.57 | ||
Other(s) | 13 (4.6) | 8 (3.5) | 5 (9.3) | 0.14 | ||
Clinical presentation | ||||||
APACHE II score, median (IQR) | 18 (12–24) | 15 (11–21) | 26 (21–33.3) | < 0.001 | ||
Pitt bacteremia score, median (IQR) | 2 (1–6) | 1 (0–3) | 8 (4.75–10.5) | < 0.001 | 1.24 (1.13–1.36) | < 0.001 |
Charlson comorbidity index, median (IQR) | 2 (1–4) | 2 (1–4) | 3 (2–5) | 0.02 | 1.24 (1.09–1.41) | 0.001 |
Septic shock | 69 (24.2) | 30 (13.0) | 39 (72.2) | < 0.001 | 2.61 (1.28–5.35) | 0.009 |
MODS | 48 (16.8) | 19 (8.2) | 29 (53.7) | < 0.001 | ||
Immunosuppression state | 94 (33.0) | 67 (29.0) | 27 (50.0) | 0.003 | ||
Therapy | ||||||
Appropriate empiric therapy | 189 (66.3) | 163 (70.6) | 26 (48.1) | 0.002 | ||
Appropriate definitive therapy | 230 (80.7) | 194 (84.0) | 36 (66.7) | 0.004 | ||
HM phenotype | 69 (24.2) | 61 (26.4) | 8 (14.8) | 0.08 | ||
bla KPC | 95 (33.3) | 53 (22.9) | 42 (77.8) | < 0.001 | 2.20 (1.06–4.54) | 0.034 |
rmpA | 90 (31.6) | 83 (35.9) | 7 (13.0) | 0.001 | ||